Function of low ADARB1 expression in lung adenocarcinoma

Area of Science:

• Molecular Biology
• Oncology
• Bioinformatics

Background:

• Adenosine deaminase RNA-specific B1 (ADARB1) is an A-to-I RNA editing enzyme implicated in cancer development.
• The specific role of ADARB1 in lung adenocarcinoma (LUAD) remains incompletely understood, necessitating further investigation.

Purpose of the Study:

• To elucidate the detailed function of ADARB1 in LUAD using integrative bioinformatics.
• To evaluate ADARB1 as a potential diagnostic and prognostic biomarker for LUAD patients.

Main Methods:

• Bioinformatic analyses of public databases (GEPIA, GE-mini, Oncomine, Wanderer).
• Experimental validation including RT-PCR, Western blot, and Wound Healing Assay.
• Investigation of ADARB1 expression changes upon treatment with a DNMT inhibitor (5-azaD).

Main Results:

• Significantly decreased ADARB1 expression was observed in LUAD tissues and cells compared to normal controls.
• ADARB1 knockdown promoted LUAD cell metastasis, and its downregulation correlated with shorter survival times (FP, OS, PPS).
• ADARB1 expression and methylation were significantly associated with LUAD clinical characteristics; 5-azaD treatment upregulated ADARB1 and reversed migration inhibition.

Conclusions:

• Low ADARB1 levels are a specific finding in LUAD.
• ADARB1 may serve as a potential diagnostic and prognostic biomarker for LUAD.
• Modulating ADARB1 expression could be a therapeutic strategy for LUAD.